Stockreport

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

AC Immune SA  (ACIU) 
Last ac immune sa earnings: 11/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
PDF AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to [Read more]